Published in Thromb Haemost on July 01, 2000
Renewed interest in haemostasis changes induced by oral contraceptives (OCs) Thromb Haemost (2000) 1.41
Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med (2008) 0.88
Evaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study. Respir Res (2014) 0.78
Plasma concentrations of D-dimer and outcome of in vitro fertilization. J Ovarian Res (2014) 0.77
A Case of Oral-contraceptive Related Ischemic Colitis in Young Woman. Clin Endosc (2011) 0.75
Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study. PLoS One (2014) 0.75
Empirical evidence of design-related bias in studies of diagnostic tests. JAMA (1999) 12.96
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
Once versus thrice daily gentamicin in patients with serious infections. Lancet (1993) 4.92
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med (1997) 3.26
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost (2011) 2.69
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem (1981) 2.39
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem (1980) 2.39
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
Meta-analysis: the final answer, or even more confusion? Lancet (1996) 2.24
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost (1999) 2.18
Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet (1994) 2.18
Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev (2004) 2.16
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost (2013) 2.15
Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg (2011) 2.14
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost (2012) 2.09
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost (2014) 2.03
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00
Deep-vein thrombosis. Lancet (1999) 1.98
Triage of patients for short term observation after elective coronary angioplasty. Heart (2000) 1.97
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Application of treatment thresholds to diagnostic-test evaluation: an alternative to the comparison of areas under receiver operating characteristic curves. Med Decis Making (1997) 1.96
Compression ultrasonography of the leg veins in patients with clinically suspected pulmonary embolism: is a more extensive assessment of compressibility useful? Thromb Haemost (2000) 1.95
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
An alternating site sequence for oxidative phosphorylation suggested by measurement of substrate binding patterns and exchange reaction inhibitions. J Biol Chem (1977) 1.94
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2004) 1.84
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol (1997) 1.77
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
The value of G degrees for the hydrolysis of ATP. Biochim Biophys Acta (1972) 1.73
Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. Thromb Haemost (2000) 1.73
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med (2001) 1.72
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost (2005) 1.70
Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost (2010) 1.69
Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost (2006) 1.69
Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr (2001) 1.68
Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Br J Surg (1996) 1.68
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost (2004) 1.63
Thyroid diseases and cerebrovascular disease. Stroke (2005) 1.63
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J (2001) 1.62
The value of lung scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med (1993) 1.61
Reliable rapid blood test for the exclusion of venous thromboembolism in symptomatic outpatients. Thromb Haemost (1996) 1.61
High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol (1999) 1.60
Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost (1999) 1.60
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57